Navigation Links
Researchers query FDA about updating requirements for drug approval
Date:1/31/2008

Rockville, MD Scientists and the Food and Drug Administration (FDA) are discussing how new technologies in ophthalmology, which make it possible to collect better data about experimental treatments, might affect FDA clinical trials requirements.

Researchers from the National Institutes of Healths National Eye Institute (NEI) and major US universities and research centers met in a roundtable discussion with FDA representatives before an audience of their peers on November 28-29, 2006 in Washington DC.

The discussion among the 30 participants focused on endpoints and clinical trial strategies for evaluating new treatments for age-related macular degeneration (AMD), diabetic retinopathy and other severe retinal disorders.

The exchange is the subject of Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium, an article in the February 2008 issue of ARVOs peer-reviewed journal, Investigative Ophthalmology and Visual Science (http://www.iovs.org/cgi/content/full/49/2/479). The authors are Karl G. Csaky of Duke University Medical Center, Elaine A. Richman of Richman Associates and Frederick L. Ferris III, of NEI.

The FDA currently recommends that clinical study sponsors compare changes in visual function (measured on a visual acuity chart of letters and numbers) as a primary endpoint in assessing the effect of a new compound for treating a disorder of the eye.

Many scientists feel that the FDA parameters may not be sensitive enough for studying diseases that progress very slowly or for studying the effect of new anti-VEGF agents for treating AMD. They query whether new technologies could more efficiently detect a treatments effectiveness, thereby hastening the translation of clinical trials into better treatments in the doctors office.

Such new technologies include optical coherence tomography (OCT), a scanning technology that maps, in 3-D, the minute hills and valleys of the retina.

Scientists suggested the FDA consider other endpoints, like OCT-detected changes in the thickness of the retina or the disappearance of problem blood vessels.

The FDA position is firm yet open. FDA representatives reminded researchers that the FDA sets a high bar for new drug approvals.

The agency might consider a lower bar and different endpoints for clinical trials, provided the degree of risk to the patient is correspondingly smaller and the trial sponsor is able to justify the clinical relevance of the new endpoints.

The FDA representatives also explained several new standards for drugs when two products are used in combination (called combination products or multi-agent products).

The report also reflects discussions about drug safety, post-marketing drug surveillance between eye study designs, mechanisms for obtaining and substantiating data for retinal disease post-marketing, and whether statistically significant differences in visual function outcomes are clinically important.


'/>"/>

Contact: Joanne Olson
jolson@arvo.org
240-221-2923
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Related medicine news :

1. MITs McGovern Institute researchers awarded $8.5M to study brain basis of autism and dyslexia
2. U of M researchers discover a pathway to turn off immune system cells
3. Oregon researchers find trigger gene for muscle development
4. Researchers uncover more about how poxviruses evade the immune system
5. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
6. Penn researchers discover new target for preventing and treating flu
7. Researchers investigate links between prostate, cadmium, zinc
8. New nanotube findings by Stanford researchers give boost to potential biomedical applications
9. Researchers Map Paths Governing Neuron Function
10. Cold Spring Harbor Laboratory researchers race against time to save Tasmanian devils
11. Researchers at Peoria Pulmonary Associates to study airway bypass procedure for emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) ... per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks ... (WCRI) . , According to the study, medical payments per claim in California decreased ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Little Rock, has initiated a charity ... According to the National Foundation to End Senior Hunger, Arkansas ranks first in ...
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... Coppin ... business owners and families in and around the Cape Coral area, is embarking on ... Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication to ... of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of ... both sides of the Atlantic with a mechanism to comply with EU data protection ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the drug in their bodies, a researcher at the Icahn School of Medicine ... Research. , The study found that when young children are exposed to secondhand ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  Agenovir Corporation, a company ... antiviral therapeutics, today announced that it appointed ... and a member of the board of directors. ... with a deep background in both founding and ... of Agenovir, co-president of Chan Zuckerberg  Biohub ...
(Date:12/8/2016)... NORWALK, Conn. , Dec. 8, 2016   Mederi Therapeutics Inc . has ... for Stretta Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). ... ... procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun ... , , "We ...
(Date:12/8/2016)... ANTONIO , Dec. 8, 2016 Eli ... announced that the neoMONARCH study of abemaciclib, a cyclin-dependent ... primary endpoint of reducing expression of Ki67, a biomarker ... data from the Phase 2 trial presented during the ... Cancer Symposium (SABCS) evaluated abemaciclib, both alone or in ...
Breaking Medicine Technology: